For older adults at risk for cognitive decline, especially those with remitted major depressive disorder (rMDD) — with or without mild cognitive impairment (MCI) — cognitive remediation (CR) plus ...
Komzifti, a menin inhibitor, is FDA-approved for relapsed/refractory AML with NPM1 mutation, showing efficacy in the KO-MEN-001 trial. The trial reported a 21.4% CR plus CRh rate and a five-month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results